Prognostic analysis of first-recurrence/metastasis esophageal squamous cell carcinoma: chemoimmunotherapy combined with radiotherapy as one of the optimal clinical management strategies - Takeaways - MDSpire

Prognostic Evaluation of First Recurrence or Metastasis in Esophageal Squamous Cell Carcinoma: The Role of Combined Chemoimmunotherapy and Radiotherapy in Optimal Treatment Approaches

  • By

  • Yitong Li

  • Qiaofang Li

  • Kuo Wang

  • Mengchang Gao

  • Lei Tian

  • Miaomiao Liu

  • Yuqing Bu

  • Yujie Cui

  • July 21, 2026

Share

  • 1

    This study evaluated 156 patients with first-recurrent/metastatic esophageal squamous cell carcinoma treated from January 2018 to January 2023.

  • 2

    The combined Immunotherapy+Radiotherapy+Chemotherapy group showed a lower incidence of progressive disease compared to the Chemotherapy+Immunotherapy group.

  • 3

    First-line treatment was identified as an independent factor affecting progression-free survival, with better outcomes in the IT+RT+CT group.

  • 4

    The IT+RT+CT regimen was significantly associated with improved overall survival compared to the CT+IT regimen in both first-line and subsequent-line treatments.

  • 5

    The findings suggest that IT+RT+CT may prolong progression-free and overall survival in recurrent/metastatic ESCC, pending validation in prospective studies.

Original Source(s)

Prognostic analysis of first-recurrence/metastasis esophageal squamous cell carcinoma: chemoimmunotherapy combined with radiotherapy as one of the optimal clinical management strategies

  • by Yitong Li, Qiaofang Li, Kuo Wang, Mengchang Gao, Lei Tian, Miaomiao Liu, Yuqing Bu, Yujie Cui

  • July 21, 2026

Related Content

SCC-Net: A lightweight attention-enhanced deep learning model for automated squamous cell carcinoma detection

Foundation model-enhanced multimodal radiomics for predicting response to chemo-immunotherapy in advanced lung squamous cell carcinoma

The CpG island methylator phenotype defines an immune-cold and therapy-resistant subtype of cutaneous melanoma